• Publications
  • Influence
Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030
Based on published prevalence studies, we used two different methodologies to project the number of individuals with Parkinson disease (PD) in Western Europe’s 5 most and the world’s 10 most populousExpand
  • 1,664
  • 54
Detection of Huntington’s disease decades before diagnosis: the Predict-HD study
Objective: The objective of the Predict-HD study is to use genetic, neurobiological and refined clinical markers to understand the early progression of Huntington’s disease (HD), prior to the pointExpand
  • 635
  • 37
  • PDF
Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial.
BACKGROUND The best way to initiate dopaminergic therapy for early Parkinson disease remains unclear. OBJECTIVE To compare initial treatment with pramipexole vs levodopa in early Parkinson disease,Expand
  • 557
  • 21
Neurocognitive signs in prodromal Huntington disease.
OBJECTIVE PREDICT-HD is a large-scale international study of people with the Huntington disease (HD) CAG-repeat expansion who are not yet diagnosed with HD. The objective of this study was toExpand
  • 310
  • 16
Detecting and monitoring the symptoms of Parkinson's disease using smartphones: A pilot study.
BACKGROUND Remote, non-invasive and objective tests that can be used to support expert diagnosis for Parkinson's disease (PD) are lacking. METHODS Participants underwent baseline in-clinicExpand
  • 197
  • 10
  • PDF
Randomized Controlled Clinical Trial of 'Virtual House Calls' for Parkinson Disease
IMPORTANCE The burden of neurological disorders is increasing, but access to care is limited. Providing specialty care to patients via telemedicine could help alleviate this growing problem. Expand
  • 121
  • 6
  • PDF
Motor abnormalities in premanifest persons with Huntington's disease: The PREDICT‐HD study
The PREDICT‐HD study seeks to identify clinical and biological markers of Huntington's disease in premanifest individuals who have undergone predictive genetic testing. We compared baseline motorExpand
  • 125
  • 5
Atomoxetine for the treatment of executive dysfunction in Parkinson's disease: A pilot open‐label study
Executive dysfunction (ED) is a prominent and often disabling feature of cognitive impairment in Parkinson's disease (PD). Few studies have examined treatments. Given the role of noradrenergicExpand
  • 108
  • 4
Natural history of Huntington disease.
IMPORTANCE Understanding the natural history of Huntington disease will inform patients and clinicians on the disease course and researchers on the design of clinical trials. OBJECTIVE To determineExpand
  • 81
  • 4
  • PDF
Characterization of the Huntington intermediate CAG repeat expansion phenotype in PHAROS
Objectives: We aimed to describe the clinical phenotype conferred by the intermediate-length huntingtin allele CAG repeat expansion in a population-based study. Methods: The Prospective Huntington AtExpand
  • 68
  • 4